MP-0274

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMP-0274

Drug Alias NameSPA-28CME-114CME-115CME-118CME-119 +[7]

ClassificationBiologics

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermanySwitzerlandUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMolecular Partners Ag

China Registration ClassN/A

Develop Information

Active CompaniesMolecular Partners Ag

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A